Most people with<unk>  are successfully treated and survive for many years. However, if the initial treatment is unsuccessful, or if it returns, the long-term prognosis is worse. Relapses generally appear within 12 to 18 months after the completion of treatment.
Primary mediastinal B-cell lymphoma
Thymic carcinoma
Thymoma with immunodeficiency
Tuberculous lymphadenitis
Nodal marginal zone B cell lymphoma
Primary effusion lymphoma
Gray zone lymphoma
Thymoma-associated multiorgan autoimmunity